CNS Metastases in Patients With MET Exon 14–Altered Lung Cancers and Outcomes With Crizotinib

PURPOSE: Although MET exon 14 (METex14)–altered lung cancers were first identified more than a decade and a half ago, the frequency of CNS metastatic disease remains poorly defined. Furthermore, the seminal trial of crizotinib in these patients (PROFILE 1001) did not report patterns of CNS response...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:JCO Precis Oncol
Glavni autori: Offin, Michael, Luo, Jia, Guo, Robin, Lyo, John K., Falcon, Christina, Dienstag, Jordan, Wilkins, Olivia, Chang, Jason, Rudin, Charles M., Riely, Gregory, Rekhtman, Natasha, Arcila, Maria E., Heller, Glenn, Ladanyi, Marc, Li, Bob T., Kris, Mark G., Paik, Paul, Drilon, Alexander
Format: Artigo
Jezik:Inglês
Izdano: American Society of Clinical Oncology 2020
Teme:
Original Reports
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7446485/
https://ncbi.nlm.nih.gov/pubmed/32923895
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/PO.20.00098
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items